Monte Rosa Therapeutics Inc.
GLUE | NASDAQ
$12.26
+$0.13 (+1.07%)
At close: Sep 21, 2026, 4:00 PM ET
$12.34
+$0.08 (+0.65%)
Pre-market:
Sep 22, 2026, 5:22 AM ET
Fiscal Quarter Period Ending | Q2 2026 Jun 29, 2026 | Q1 2026 Mar 30, 2026 | Q4 2025 Dec 30, 2025 | Q3 2025 Sep 29, 2025 | Q2 2025 Jun 29, 2025 | Q1 2025 Mar 30, 2025 | Q4 2024 Dec 30, 2024 | Q3 2024 Sep 29, 2024 | Q2 2024 Jun 29, 2024 | Q1 2024 Mar 30, 2024 | Q4 2023 Dec 30, 2023 | Q3 2023 Sep 29, 2023 | Q2 2023 Jun 29, 2023 | Q1 2023 Mar 30, 2023 | Q4 2022 Dec 30, 2022 | Q3 2022 Sep 29, 2022 | Q2 2022 Jun 29, 2022 | Q1 2022 Mar 30, 2022 | Q4 2021 Dec 30, 2021 | Q3 2021 Sep 29, 2021 | Q2 2021 Jun 29, 2021 | Q1 2021 Mar 30, 2021 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | 8.97M | 4.21M | 2.78M | 12.77M | 23.19M | 84.93M | 60.65M | 9.22M | 4.7M | 1.06M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost of Revenue | n/a | 2.03M | n/a | n/a | n/a | n/a | n/a | n/a | 2.06M | 1.9M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Gross Profit | 8.97M | 2.18M | 2.78M | 12.77M | 23.19M | 84.93M | 60.65M | 9.22M | 2.64M | -833K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Income | -49.13M | -50.03M | -49.72M | -32.98M | -15.55M | 44.04M | 13M | -26.53M | -32.64M | -34.95M | -34.86M | -36.97M | -37.22M | -34.26M | -32.49M | -28.36M | -27.23M | -24.3M | -23.39M | -19.87M | -18.12M | -11.5M |
Interest Income | 5.92M | 5.59M | 3.69M | 2.75M | 3.07M | 3.44M | 2.6M | 2.89M | 2.64M | 2.44M | 2.37M | 2.23M | 2.3M | 2.44M | 1.99M | 997K | 628K | 149K | 13K | 13K | 14K | 6K |
Pretax Income | -43.19M | -44.45M | -46.08M | -30.26M | -11.1M | 47.71M | 15.6M | -23.79M | -30.06M | -31.89M | -33.27M | -34.71M | -34.99M | -32.04M | -30.78M | -27.32M | -26.47M | -23.93M | -23.44M | -19.84M | -18.41M | -12.28M |
Net Income | -43.4M | -44.5M | -46.14M | -27.08M | -12.3M | 46.89M | 13.44M | -23.86M | -30.31M | -31.97M | -33.25M | -34.88M | -35.18M | -32.04M | -30.78M | -27.32M | -26.47M | -23.93M | -23.44M | -19.84M | -18.41M | -12.28M |
Selling & General & Admin | 10.13M | 10.18M | 10.52M | 9.07M | 8.1M | 8.7M | 8.78M | 8.13M | 9.28M | 8.99M | 7.73M | 8.66M | 8.15M | 7.5M | 7.62M | 7.02M | 6.3M | 6.39M | 5.26M | 4.75M | 3.49M | 2.23M |
Research & Development | 47.96M | 44.07M | 41.98M | 36.68M | 30.65M | 32.19M | 38.87M | 27.62M | 26M | 25.13M | 27.14M | 28.31M | 29.08M | 26.76M | 24.87M | 21.34M | 20.94M | 17.92M | 18.13M | 15.12M | 14.64M | 9.27M |
Other Expenses | n/a | -2.03M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 1K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Expenses | 58.1M | 52.22M | 52.5M | 45.74M | 38.75M | 40.89M | 47.64M | 35.74M | 35.28M | 34.11M | 34.86M | 36.97M | 37.22M | 34.26M | 32.49M | 28.36M | 27.23M | 24.3M | 23.39M | 19.87M | 18.12M | 11.5M |
Interest Expense | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 58.1M | 54.24M | 52.5M | 45.74M | 38.75M | 40.89M | 47.64M | 35.74M | 37.34M | 36.01M | 34.86M | 36.97M | 37.22M | 34.26M | 32.49M | 28.36M | 27.23M | 24.3M | 23.39M | 19.87M | 18.12M | 11.5M |
Income Tax Expense | 208K | 52K | 59K | -3.18M | 1.2M | 822K | 2.16M | 71K | 252K | 83K | -22K | 170K | 190K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Shares Outstanding (Basic) | 101.48M | 65.54M | 65.54M | 82.4M | 82.19M | 82.15M | 61.44M | 82.01M | 71.23M | 60.16M | 56.93M | 49.81M | 49.43M | 49.35M | 48.89M | 46.73M | 46.67M | 46.6M | 45.99M | 45.99M | 45.99M | 42.54M |
Shares Outstanding (Diluted) | 101.48M | 65.54M | 65.54M | 82.4M | 82.19M | 82.96M | 61.44M | 82.01M | 71.23M | 60.16M | 56.93M | 49.81M | 49.43M | 49.35M | 48.89M | 46.73M | 46.67M | 46.6M | 45.99M | 45.99M | 45.99M | 42.54M |
EPS (Basic) | -0.43 | -0.68 | -0.70 | -0.33 | -0.15 | 0.57 | 0.22 | -0.29 | -0.43 | -0.53 | -0.58 | -0.70 | -0.71 | -0.60 | -0.59 | -0.56 | -0.55 | -0.51 | -0.51 | -0.43 | -3.63 | -0.29 |
EPS (Diluted) | -0.43 | -0.68 | -0.70 | -0.33 | -0.15 | 0.57 | 0.22 | -0.29 | -0.43 | -0.53 | -0.58 | -0.70 | -0.71 | -0.60 | -0.59 | -0.56 | -0.55 | -0.51 | -0.51 | -0.43 | -3.63 | -0.29 |
EBITDA | -41.28M | -42.42M | -43.99M | -28.16M | -8.97M | 49.76M | 17.66M | -21.69M | -28M | -29.99M | -31.43M | -35.13M | -33.6M | -30.89M | -29.71M | -26.29M | -25.58M | -23.18M | -22.63M | -19.26M | -17.94M | -11.23M |
EBIT | -43.19M | -44.45M | -46.08M | -30.26M | -11.1M | 47.71M | 15.6M | -23.79M | -30.06M | -31.89M | -33.27M | -36.97M | -34.99M | -32.04M | -30.78M | -27.32M | -26.47M | -23.93M | -23.44M | -19.84M | -18.41M | -11.5M |
Depreciation & Amortization | 1.91M | 2.03M | 2.09M | 2.1M | 2.13M | 2.05M | 2.06M | 2.1M | 2.06M | 1.9M | 1.85M | 1.83M | 1.39M | 1.15M | 1.07M | 1.03M | 889K | 753K | 809K | 582K | 467K | 274K |
Add to Watchlist
Select watchlists to add or remove GLUE